2024 Research Innovation and Impact Grant Recipients Announced

2024 Research Innovation and Impact Grant Recipients Announced
18.10.2024

The RPH Research Foundation is proud to announce the recipients of the 2024 Research Innovation and Impact Grants. 2024 Research Innovation and Impact Grants are a Program of the Western Australian (WA) Future Health Research and Innovation (FHRI) Fund and the RPH Research Foundation.

Thanks to matched co-funding from the FHRI Fund, the RPH Research Foundation has awarded a total of $3,526,670 across three innovative research projects.  

These grants support mid-career and senior researchers who are translating their ideas into healthcare innovations that could lead to a significant impact on the health and wellbeing of our community.

The three projects will be led by researchers at the Royal Perth Hospital and address critical health challenges to improve Western Australian patient outcomes. From developing highly effective personalised Chimeric antigen receptor (CAR) T-cells to help treat incurable cancers to using machine learning to predict cardiovascular complications after non-cardiac surgery, these innovative projects are challenging existing paradigms.

Congratulations to the 2024 Research Innovation and Impact Grants recipients:  

A Pathway to Preventing Leukaemia
$1,147,285
Coordinating Principal Investigator: Dr Hun Chuah

Using the WA-invented Immuno-flowFISH, the team aim to develop a pathway to detect, predict and prevent leukaemia to allow clinicians to intervene earlier with treatment.

Read More 

Artificial intelligence to Improve Outcomes after Surgery
$1,179,424
Lead Investigator: Professor Graham Hillis 

Cardiovascular complications after surgery are difficult to predict. This project will utilise machine learning to analyse data to identify patients at risk before and after surgery.

Read More 

Personalised Place-of-care Manufactured Immune cells for Blood Cancer
$1,199,901
Coordinating Principal Investigator: Associate Professor Agnes Yong 

Every year, 2,500 Australians are diagnosed with Myeloma, an incurable cancer. This project will manufacture personalised BCMA-CAR T-cells for patients who have exhausted all other treatment options.

Read More 

SHARE TO
Go to Top of the page